← Guangzhou Wondfo Biotech overview

Guangzhou Wondfo Biotech vs Boston Scientific: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Boston Scientific Corp (BSX)

Q3 2026
▼3▲1

BSX hit by guidance cuts, cyberattack, recalls despite pipeline bets

  • Guidance cut twice on WATCHMAN weakness and lost EP share Boston Scientific lowered its 2026 profit outlook twice, first because its WATCHMAN heart implant sold poorly and it lost share in electrophysiology, then again after an August cyberattack disrupted orders and shipping.

    Repeated guidance cuts are the main negative force that pushed the stock down during the quarter.

  • August cyberattack disrupted orders and shipping A cyberattack in August forced another guidance cut, with the company unable to say how much the disruption would cost. Orders and shipping were affected, hurting sales in the quarter.

    This was a new, unexpected operational shock that directly hurt results and investor confidence.

  • Recalls and Citi downgrade on rising competition Multiple product recalls, including a serious Class I recall of the ENROUTE device, raised regulatory and reputational concerns. Citi downgraded the stock to Neutral, expecting Boston Scientific to lose more share to Abbott's Amulet in 2027.

    These events added regulatory and competitive pressure that weighed on the stock.

  • Pipeline investments and Penumbra acquisition support long-term growth Boston Scientific invested $1.5B in MiRus, secured a $3B TAVR option, and agreed to buy Penumbra for $14.5B to expand clot-removal technology. These bets slightly dilute near-term earnings but aim to strengthen future growth.

    These are the main positive strategic moves that could offset current troubles over the long run.

September 2026
▼3▲1

Cyberattack cuts guidance, Penumbra deal offsets, competition and recalls weigh

  • Cyberattack forces guidance cut The August cyberattack disrupted manufacturing and shipping, so BSX now expects to miss its 2026 sales and profit targets. The full cost is unknown, and the updated outlook comes October 28. This uncertainty pushes the stock down because investors can't yet measure the damage.

    This is the main new negative event that directly caused the guidance cut and stock drop.

  • Weak WATCHMAN and EP businesses lower 2026 outlook BSX cut its 2026 growth and earnings outlook because its WATCHMAN heart implant and electrophysiology businesses are weak. Management expects pressure into 2027, with growth below the market rate. This lowers near-term profit expectations and weighs on the stock.

    This explains the fundamental business weakness behind the lowered guidance, separate from the cyberattack.

  • Penumbra acquisition expands clot-removal business BSX agreed to buy Penumbra for $14.5 billion, adding blood-clot removal technology to its heart division. The deal will slightly reduce earnings per share at first (6-8 cents) but is expected to improve later. It signals long-term growth and supports the stock.

    This is a major new strategic move that offsets some negative sentiment and shows future growth potential.

  • Citi downgrade and new competition Citi downgraded BSX to Neutral, warning of rising competition in heart procedures and expected market-share loss to Abbott's Amulet device in 2027. New proposed guidelines could also hurt WATCHMAN sales. This adds pressure on the stock as investors worry about future growth.

    This is a fresh analyst downgrade highlighting competitive and regulatory risks that directly affect BSX's valuation.

Latest
▼3▲1

Cyberattack cuts guidance, Penumbra deal offsets, competition and recalls weigh

  • Cyberattack forces guidance cut The August cyberattack disrupted manufacturing and shipping, so BSX now expects to miss its 2026 sales and profit targets. The full cost is unknown, and the updated outlook comes October 28. This uncertainty pushes the stock down because investors can't yet measure the damage.

    This is the main new negative event that directly caused the guidance cut and stock drop.

  • Weak WATCHMAN and EP businesses lower 2026 outlook BSX cut its 2026 growth and earnings outlook because its WATCHMAN heart implant and electrophysiology businesses are weak. Management expects pressure into 2027, with growth below the market rate. This lowers near-term profit expectations and weighs on the stock.

    This explains the fundamental business weakness behind the lowered guidance, separate from the cyberattack.

  • Penumbra acquisition expands clot-removal business BSX agreed to buy Penumbra for $14.5 billion, adding blood-clot removal technology to its heart division. The deal will slightly reduce earnings per share at first (6-8 cents) but is expected to improve later. It signals long-term growth and supports the stock.

    This is a major new strategic move that offsets some negative sentiment and shows future growth potential.

  • Citi downgrade and new competition Citi downgraded BSX to Neutral, warning of rising competition in heart procedures and expected market-share loss to Abbott's Amulet device in 2027. New proposed guidelines could also hurt WATCHMAN sales. This adds pressure on the stock as investors worry about future growth.

    This is a fresh analyst downgrade highlighting competitive and regulatory risks that directly affect BSX's valuation.

August 2026
▼2

BSX hit by cyberattack and recalls as growth outlook weakens

  • Cybersecurity incident disrupts orders and shipments BSX disclosed a cyberattack that disrupted IT systems worldwide, hurting its ability to process and ship customer orders. The stock fell as much as 5.9% in one day. The financial cost is still unknown, so investors face uncertainty about lost sales and cleanup expenses.

    This is the biggest new event of the period and directly explains the sharp price drop.

  • New worldwide recalls add regulatory and reputational pressure BSX issued multiple recalls, including a serious Class I recall of its ENROUTE neuroprotection system and Class II recalls of OverStitch devices. These affect high-risk procedures and could disrupt hospital ordering. Recalls raise costs, invite regulatory scrutiny, and can damage trust with doctors and patients.

    This is a fresh negative event that adds to the company's operational and reputational problems.

▼2

BSX hit by cyberattack and recalls as growth outlook weakens

  • Cybersecurity incident disrupts orders and shipments BSX disclosed a cyberattack that disrupted IT systems worldwide, hurting its ability to process and ship customer orders. The stock fell as much as 5.9% in one day. The financial cost is still unknown, so investors face uncertainty about lost sales and cleanup expenses.

    This is the biggest new event of the period and directly explains the sharp price drop.

  • New worldwide recalls add regulatory and reputational pressure BSX issued multiple recalls, including a serious Class I recall of its ENROUTE neuroprotection system and Class II recalls of OverStitch devices. These affect high-risk procedures and could disrupt hospital ordering. Recalls raise costs, invite regulatory scrutiny, and can damage trust with doctors and patients.

    This is a fresh negative event that adds to the company's operational and reputational problems.

July 2026
▲2▼2

BSX beat Q2 but cut guidance twice on WATCHMAN and EP share losses

  • Guidance cut twice on WATCHMAN weakness and lost EP share Boston Scientific lowered its 2026 outlook twice, blaming weak demand for its WATCHMAN heart implant and lost U.S. electrophysiology market share. This directly hurt investor confidence and near-term profit expectations.

    The repeated guidance cuts are the main negative force on the stock this period.

  • Q2 beat and $500M restructuring savings plan The company beat second-quarter estimates and launched a restructuring aimed at saving $500 million a year by 2029. Cost cuts can protect profits while sales growth is slow.

    This is a new positive offset to the weak demand and share-loss news.

  • $1.5B MiRus stake and $3B TAVR option Boston Scientific invested $1.5 billion for a 34% stake in MiRus and secured an exclusive $3 billion option to buy a TAVR heart-valve business. This expands its cardiology pipeline for future growth.

    A major new capital deployment that supports the longer-term growth story.

  • Multiple recalls raise safety and regulatory concerns Recalls hit CRE endoscopy devices, ENROUTE catheters (FDA warning after tip separation), FARADRIVE ablation generators, vascular sheaths, and Orca valves. These quality problems add regulatory and reputational risk.

    The wave of recalls is a new negative that weighs on trust and future sales.

▼3▲1

BSX cuts 2026 outlook on WATCHMAN and EP weakness; recalls add pressure

  • 2026 guidance cut on WATCHMAN and electrophysiology weakness Boston Scientific lowered its 2026 sales growth and earnings guidance, citing weaker WATCHMAN heart-implant demand and lost U.S. electrophysiology market share. This directly reduces expected future profits, pushing the stock down as investors reprice slower growth.

    This is the core new event that answers why BSX is moving now.

  • New recalls of cardiac ablation generators and vascular sheaths Boston Scientific recalled cardiac ablation generators and vascular sheaths due to labeling errors and air embolism risks, covering over 700,000 FARADRIVE units. This raises regulatory and safety concerns, potentially hurting sales and reputation in key heart-rhythm products.

    A fresh recall event that adds to negative pressure on the stock.

  • $1.5B MiRus investment with TAVR acquisition option Boston Scientific invested $1.5 billion for a 34% stake in MiRus and gained an exclusive option to buy its advanced TAVR heart-valve system for $3 billion. This expands its interventional cardiology pipeline with a less invasive option, supporting longer-term growth.

    A new strategic investment that could lift future growth prospects.

  • Nationwide recall of Orca valves Boston Scientific voluntarily recalled its Orca Single Use Air/Water and Suction Valves nationwide after a device malfunction. This adds operational and regulatory scrutiny, potentially disrupting hospital procedures and weighing on near-term sales.

    A new recall event that contributes to the negative news flow.

▼2▲1

BSX swings on recalls, restructuring, and mixed Q2 guidance

  • Sterile-packaging recalls raise quality and regulatory risk Boston Scientific recalled tens of thousands of CRE endoscopy devices worldwide due to sterile packaging breaches. This adds regulatory and quality-control concerns, potentially pressuring margins and brand trust in the endoscopy segment, and may reinforce worries about integration risk as the company scales.

    New recall event that introduces regulatory and quality risk, directly affecting BSX's outlook.

  • FDA warns on ENROUTE catheters after tip separation reports The FDA advised avoiding certain lots of Boston Scientific's ENROUTE catheters after reports of tip separation, including one serious injury. This raises safety and regulatory concerns, potentially leading to product liability, sales impact, and reputational damage in the neurovascular space.

    New FDA warning that adds regulatory and safety risk, directly affecting BSX's product sales and reputation.

  • Restructuring plan aims to cut $500M in annual costs Boston Scientific announced a global restructuring with job cuts, expecting $700–800 million in costs but $500 million in annual pre-tax savings by 2029. This should boost profitability and fund growth areas like FARAPULSE and WATCHMAN, though it signals pressure in some segments.

    New restructuring initiative that directly impacts future profitability and resource allocation.

  • Q2 beat but 2026 guidance trimmed, then stock rebounds Boston Scientific beat Q2 earnings and revenue estimates, but trimmed full-year EPS and sales growth guidance, initially sending shares down 5%. The next day, shares rose 7.1% as investors focused on the beat and raised sales outlook, though guidance remains below consensus.

    New quarterly results and guidance change that directly drive stock movement and investor sentiment.

© 2026 MarketDXWhy